G1 Therapeutics, Inc. (NASDAQ:GTHX – Get Rating) insider Rajesh Malik sold 18,000 shares of G1 Therapeutics stock in a transaction that occurred on Tuesday, September 13th. The stock was sold at an average price of $15.71, for a total value of $282,780.00. Following the completion of the sale, the insider now owns 73,207 shares of the company’s stock, valued at $1,150,081.97. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
G1 Therapeutics Stock Down 1.6 %
Shares of NASDAQ:GTHX opened at $15.21 on Friday. The stock has a market cap of $650.23 million, a price-to-earnings ratio of -3.79 and a beta of 1.93. The company has a quick ratio of 4.38, a current ratio of 4.75 and a debt-to-equity ratio of 1.15. G1 Therapeutics, Inc. has a 12-month low of $3.84 and a 12-month high of $17.49. The business’s 50 day moving average is $11.76 and its 200 day moving average is $8.22.
G1 Therapeutics (NASDAQ:GTHX – Get Rating) last announced its earnings results on Wednesday, August 3rd. The company reported ($0.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.04) by $0.12. The company had revenue of $10.57 million for the quarter, compared to analysts’ expectations of $9.00 million. G1 Therapeutics had a negative return on equity of 140.17% and a negative net margin of 608.36%. On average, sell-side analysts forecast that G1 Therapeutics, Inc. will post -3.51 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
A number of equities research analysts have weighed in on GTHX shares. HC Wainwright reiterated a “buy” rating and issued a $67.00 target price on shares of G1 Therapeutics in a report on Friday, June 3rd. Needham & Company LLC decreased their price objective on G1 Therapeutics from $42.00 to $32.00 and set a “buy” rating for the company in a report on Thursday, August 4th. Finally, Wedbush boosted their price objective on G1 Therapeutics from $20.00 to $25.00 and gave the company an “outperform” rating in a report on Friday. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $36.83.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.
- Get a free copy of the StockNews.com research report on G1 Therapeutics (GTHX)
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
- No One Told These 3 Stocks It’s a Down Week
- Is There a Cure for What is Ailing Teladoc Stock?
- MarketBeat: Week in Review 9/12 – 9/16
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.